Crucially, they found that KRT19 maintains substantially methylated in the non-tumorigenic MCF-10-A cell line; conversely, KRT19 presents hypomethylated in the MCF-7 and MDA-MB-231 breast cancer lines, associated with an obtained increased expression for KRT19 in the transformed cell lines. The gene discussed is KRT19; the disease is breast cancer.